The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.